Amphion Innovations plc

Related Party Transaction

London and New York, 11 October 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, provides further details on the Deed of Postponement as announced on 29 September 2017 in the Company’s interim results.

Certain directors of the Company, being Richard Morgan and Robert Bertoldi (the “Directors”), entered into a Deed  of Postponement with the Company on 15 May 2017 where they agreed to postpone the repayment of the amounts owed to them by the Company as at 31 December 2016, which total US$4.3 million, plus any interest which may accrue thereon (“Director Debt”) until all other debts of the Company are repaid. Furthermore, the Directors agreed that any amount owed by the Company other than the Director Debt (the “Debt”) shall rank for all purposes and at all times ahead of the Director Debt.

Richard Morgan and Robert Bertoldi are directors of the Company and have an interest in approximately 23,642,499 and 6,436,431 Ordinary Shares respectively (representing an interest of approximately 11.39% and 3.10% of the Existing Ordinary Shares respectively). By virtue of Mr Morgan and Mr Bertoldi being directors in addition to Mr Morgan’s current interests in the Company, the Directors are considered to be a related party as defined under the AIM Rules. Thus, entering into the Deed of Postponement constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules.

The independent directors, being Richard Mansell-Jones and Miroslaw Izienicki, consider, having consulted with the Company's nominated adviser, Panmure Gordon, that the terms of the Deed of Postponement as entered into by the Company with the Directors are fair and reasonable insofar as the Company's Shareholders are concerned.


For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Mike Wort / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.